Abbott India Q1 PAT rises 5% YoY to Rs 205 cr

11 Aug 2022 , 12:19 PM

Revenue from operations was at Rs 1,304.37 crore for the quarter ended 30 June 2022 as against Rs 1,217.83 crore during the same period in the previous year, registering a growth of 7.1%. The drug makers profit before tax increased 4.4% to Rs 275.19 crore in Q1 FY23 from Rs 263.59 crore in Q1 FY22. Total expenses rose 8.43% year on year to Rs 1,055.54 crore in the quarter ended 30 June 2022. Cost of materials consumed stood at Rs 158.08 crore (up 31.18% YoY) and employee benefits expense was at Rs 152.09 crore (up 4.55% YoY). Abbott India has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. Shares of Abbott India declined 1.36% to Rs 19,341.90 on the BSE. Powered by Capital Market – Live News